Gain Therapeutics (GANX) Change in Cash (2020 - 2025)
Gain Therapeutics has reported Change in Cash over the past 6 years, most recently at $12.0 million for Q4 2025.
- Quarterly results put Change in Cash at $12.0 million for Q4 2025, up 822.19% from a year ago — trailing twelve months through Dec 2025 was $10.5 million (up 840.84% YoY), and the annual figure for FY2025 was $10.5 million, up 840.84%.
- Change in Cash for Q4 2025 was $12.0 million at Gain Therapeutics, up from $2.1 million in the prior quarter.
- Over the last five years, Change in Cash for GANX hit a ceiling of $39.1 million in Q1 2021 and a floor of -$20.0 million in Q2 2022.
- Median Change in Cash over the past 5 years was -$1.9 million (2023), compared with a mean of $668482.2.
- Peak annual rise in Change in Cash hit 6097.57% in 2021, while the deepest fall reached 695.26% in 2021.
- Gain Therapeutics' Change in Cash stood at -$4.1 million in 2021, then grew by 13.07% to -$3.6 million in 2022, then surged by 311.01% to $7.5 million in 2023, then plummeted by 122.14% to -$1.7 million in 2024, then skyrocketed by 822.19% to $12.0 million in 2025.
- The last three reported values for Change in Cash were $12.0 million (Q4 2025), $2.1 million (Q3 2025), and -$2.4 million (Q2 2025) per Business Quant data.